Evidence map›Paper›PMID 25089265›Full record

ReviewBioMed research international2014

Hepatocellular carcinoma: novel molecular targets in carcinogenesis for future therapies.

Gaetano Bertino, Shirin Demma, Annalisa Ardiri, Maria Proiti, Salvatore Gruttadauria, Adriana Toro, Giulia Malaguarnera, Nicoletta Bertino, Michele Malaguarnera, Mariano Malaguarnera and 1 more

RetractedOpen access · hybridAbstract readReviewRetracted Publication
PubMed Full text at PMC Publisher
In one paragraph

Review in BioMed research international, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It has been retracted, and should not be counted. Cited by 42 papers.

0numbers the graph read from it
0cells of the map it votes in
42citing papers in PubMed
6.4field-weighted citation impact, top 2% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

42 citing papers in PubMed, 72 citations in OpenAlex.

  1. Trial
  2. Effect ofIranian journal of basic medical sciences · 2025
    Review
  3. Article
  4. Review
  5. Article
  6. Article
  7. Review
  8. Article
  9. Article
  10. Article
  11. Article
  12. Review
  13. Article
  14. Article
  15. Article
  16. Article
  17. Observational
  18. Article
  19. Recent advances in hepatocellular carcinoma therapy.Pharmacology & therapeutics · 2017
    Review
  20. Review
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

11 authors at 1 institution in 1 country.

Gaetano BertinoHepatology Unit, Department of Medical and Pediatric Sciences, University of Catania, Policlinic, Via Santa Sofia No. 78, 95123 Catania, Italy.
Shirin DemmaHepatology Unit, Department of Medical and Pediatric Sciences, University of Catania, Policlinic, Via Santa Sofia No. 78, 95123 Catania, Italy.
Annalisa ArdiriHepatology Unit, Department of Medical and Pediatric Sciences, University of Catania, Policlinic, Via Santa Sofia No. 78, 95123 Catania, Italy.
Maria ProitiHepatology Unit, Department of Medical and Pediatric Sciences, University of Catania, Policlinic, Via Santa Sofia No. 78, 95123 Catania, Italy.
Salvatore GruttadauriaAbdominal Transplantation Unit, ISMETT Palermo, UPMC-Italy, Via Ernesto Tricomi No. 5, 90127 Palermo, Italy.
Adriana ToroDepartment of Surgical Sciences, Organ Transplantation and Advanced Technologies, University of Catania, Via Messina No. 829, 95126 Catania, Italy.
Giulia MalaguarneraResearch Centre "The Great Senescence", University of Catania, Via Messina No. 829, 95126 Catania, Italy.
Nicoletta BertinoFaculty of Pharmacy, University of Catania, Viale Andrea Doria No. 6, 95123 Catania, Italy.
Michele MalaguarneraResearch Centre "The Great Senescence", University of Catania, Via Messina No. 829, 95126 Catania, Italy.
Mariano MalaguarneraResearch Centre "The Great Senescence", University of Catania, Via Messina No. 829, 95126 Catania, Italy.
Isidoro Di CarloDepartment of Surgical Sciences, Organ Transplantation and Advanced Technologies, University of Catania, Via Messina No. 829, 95126 Catania, Italy.
University of Catania · IT

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundHepatocellular carcinoma is one of the most common and lethal malignant tumors worldwide. Over the past 15 years, the incidence of HCC has more than doubled. Due to late diagnosis and/or advanced underlying liver cirrhosis, only limited treatment options with marginal clinical benefit are available in up to 70% of patients. During the last decades, no effective conventional cytotoxic systemic therapy was available contributing to the dismal prognosis in patients with HCC. A better knowledge of molecular hepatocarcinogenesis provides today the opportunity for targeted therapy. MATERIALS AND

methodsA search of the literature was made using cancer literature, the PubMed, Scopus, and Web of Science (WOS) database for the following keywords: "hepatocellular carcinoma," "molecular hepatocarcinogenesis," "targeted therapy," and "immunotherapy." DISCUSSION AND

conclusionTreatment decisions are complex and dependent upon tumor staging, presence of portal hypertension, and the underlying degree of liver dysfunction. The knowledge of molecular hepatocarcinogenesis broadened the horizon for patients with advanced HCC. During the last years, several molecular targeted agents have been evaluated in clinical trials in advanced HCC. In the future, new therapeutic options will be represented by a blend of immunotherapy-like vaccines and T-cell modulators, supplemented by molecularly targeted inhibitors of tumor signaling pathways.

Indexed as

Gene Expression Regulation, NeoplasticAntineoplastic AgentsCarcinogenesisCarcinoma, HepatocellularEndoribonucleasesEpigenesis, GeneticGenome, HumanGenomic InstabilityGlypicansHumansImmunotherapyLiver NeoplasmsMutationProtein Kinase InhibitorsSignal TransductionTrans-ActivatorsAntineoplastic AgentsDCP1A protein, humanEndoribonucleasesGlypicansGPC3 protein, humanProtein Kinase InhibitorsTrans-Activators

Identifiers

PMID25089265
PMCPMC4096380
OpenAlexW1970127177

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.